METHODS

**Iodixanol, a New Isosmotic Nonionic Contrast Agent Compared with Iohexol in Cardiac Angiography**

James A. Hill, MD, Martin B. Cohen, MD, William H. Kou, MD, G.B. John Mancini, MD, Michael Mansour, MD, Harvey Fountaine, and Jeffrey A. Brinker, MD

Iodixanol, a new contrast agent with an osmolality equal to serum, is compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic blood pressure of >20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more P-R prolongation during left coronary angiography with iodixanol and more 5-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p < 0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should further define the role of iodixanol in cardiac angiography.

(AM J Cardiol 1994;74:57-63)

**METHODS**

Nonionic iodinated contrast agents have been widely adopted in the cardiac catheterization laboratory; the recent Society for Cardiac Angiography and Interventions registry report indicates that 72% of diagnostic catheterizations and 77% of coronary angioplastics are performed using these agents. There have been numerous studies showing that nonionic low osmolar media produce less hemodynamic and electrophysiologic effects with intracoronary injection, which seems to translate into fewer adverse clinical events. Recently, a newer nonionic agent, iodixanol, has been developed and is formulated to have an osmolality equal to serum. This agent has been shown to be safe in noncardiac applications and small studies have suggested that it is also safe for use in cardiac angiography. This study was undertaken to evaluate the hemodynamic and electrophysiologic effects of iodixanol and to compare them with a standard nonionic contrast agent, iohexol.

**METHODS**

This study was conducted at 4 sites: the University of Florida in Gainesville, the University of Michigan, New York Medical College Westchester County Medical Center, and the Johns Hopkins Hospital. Patients undergoing elective diagnostic cardiac angiography including both coronary and left ventricular angiography were screened for inclusion. Exclusion criteria were designed to eliminate patients with severe left ventricular dysfunction, aortic stenosis, or unstable clinical syndromes. The study was approved by the respective institutional review boards.

**Contrast agents:** Iohexol is a nonionic monomeric contrast agent with a molecular weight of 821.14 and iodine content of 46.36%. The concentration used for this study was the standard commercially available formulation containing 350 mg/ml of iodine with an osmolality of 844 mOsm/kg of water. Iodixanol (Visipaque™) is a nonionic dimeric contrast agent with a molecular weight of 1550.20 and iodine content of 49.1%. It is formulated to be isosmotic (290 mOsm/kg of water) with plasma by the addition of sodium and calcium chloride. The formulation used for this study contained 320 mg/ml of iodine. The chemical structures of both agents are illustrated in Figure 1.

**Catheterization procedure:** This was a randomized, double blind, parallel study. Assignment to receive either iodixanol or iohexol was performed according to a computer-generated randomization scheme specific for each site with catheterization laboratory personnel un-
aware of patients' clinical data. Angiography was performed using standard methods, and specifics of preparation and technique were left to the discretion of the investigator. The only exceptions were that use of atropine as prophylaxis for bradyarrhythmias was not allowed and that a femoral arterial sheath with a sideport 1Fr size larger than the catheter was used.

**Measurements:** Systemic blood pressure was monitored from the sideport of the femoral sheath. During coronary injections, systolic and diastolic blood pressure, heart rate, PR and QT intervals (milliseconds), and ST-segment and T-wave amplitude (millivolts) were measured. Immediately after left ventricular injection, left ventricular systolic and end-diastolic pressure were measured. During the first injection of any type (i.e., right coronary, left coronary, or left ventricular) all parameters were recorded immediately before, during, and continuously for the first 15 seconds, and again at 30, 60, and 120 seconds or until the parameter returned to baseline. With subsequent injections, these parameters were followed for 60 seconds or until the parameter returned to baseline. Any arrhythmias present after injection were also recorded, and QTc was calculated using a standard formula. After the procedure, blood pressure and heart rate were measured at 30 and 60 minutes and according to local protocol thereafter. Contrast volume with each injection and total contrast volume were recorded. Blood samples were collected at baseline, 1 hour, and 1 day after the last contrast injection and analyzed for complete blood count and chemistries. Serum creatinine and urea nitrogen were also measured 2 and 3 days after angiography.

Patients were followed for adverse events during and for 72 hours after the procedure. The actions required, intensity of the events, and outcome were tabulated. Serious adverse events included any experience that was fatal, life-threatening, or permanently disabling, or required further hospitalization. Judgment was made by the investigator regarding the causality of the event and its relation to the contrast material. Subjects were asked to evaluate any discomfort during injections according to type (heat, coldness, etc.), location, duration, and intensity.

Each injection was evaluated for the quality of visualization using cineangiograms by the blinded individual investigators. An angiogram was considered nondiagnostic if there was insufficient contrast enhancement to make a diagnosis. Angiograms considered diagnostic had sufficient contrast enhancement and were further divided into good and excellent based on qualitative observer estimation.

**Statistical analysis:** Data from all sites were combined for analysis. Fisher's exact test (2-tailed) was used for comparing contrast agent groups with respect to overall quality of visualization, adverse events, injection-associated discomfort, arrhythmias, and serum creatinine (classification being above the reference range, or change from baseline >40% of the span of the reference range). Hemodynamic parameters were analyzed by using the maximal absolute change from baseline to classify each patient as having an increase, decrease, or no change. Fisher's exact test was then used to compute group differences. Electrophysiologic parameters were analyzed using repeated-measures analysis of variance based on ranks. Differences among centers were quantified using analysis of variance with contrast agent, and center and contrast by center interaction terms in the model.

**RESULTS**

**Patient demographics:** Two hundred patients were randomized: 101 to iodixanol (81 men) and 99 to iohexol (87 men). The mean age in the iodixanol group was 61
± 10 years and in the iohexol group 59 ± 11 years (p = 0.291). All patients completed the study. There were no differences between the 2 groups with regard to indication for catheterization. Suspicion of or definite coronary artery disease was the indication for study in 92% of patients. Coronary artery disease was found in 84% and 80% of patients with iodixanol and iohexol, respectively.

**Procedural variables:** Procedure duration (39 ± 14 vs 40 ± 18 minutes), contrast volume (103 ± 46 ml vs 103 ± 37 ml), and average number of injections (9 ± 2 vs 9 ± 3) were not different between the iodixanol and iohexol groups, respectively. In both groups, 97% of patients underwent left ventriculography, and all patients except 1 in the iohexol group underwent coronary angiography.

**Image quality:** No patient in either group had a nondiagnostic study. Overall, in the iodixanol group, the quality of the angiograms was assessed as good in 41% and excellent in 59%. In the iohexol group the angiograms were assessed as good in 39% and excellent in 61% (iodixanol vs iohexol, p = 0.885).

**Hemodynamic effects:** Mean changes in systolic and diastolic pressure and heart rate occurring with first right and left coronary injection are shown in Figures 2

![Graphs showing hemodynamic changes](image-url)

**Figure 2.** Hemodynamic changes after right coronary arteriography. No significant differences are noted between iohexol and iodixanol.

**IODIXANOL IN CORONARY ANGIOGRAPHY 59**
and 3. Mean changes in systolic and end-diastolic pressures and heart rate occurring with left ventriculography are shown in Figure 4.

Because of the variability in changes in blood pressure during injection into both coronaries and the left ventricle, large changes were evaluated. The number of patients with a >20 mm Hg change in systolic and diastolic pressure during coronary angiography and >4 mm Hg change in end-diastolic pressure after ventricular injection are listed in Table I. Significantly more patients had a decrease in diastolic blood pressure of >20 mm Hg during left coronary angiography with iodixanol. There were no differences noted between the 2 agents during right coronary angiography or ventriculography.

**Electrophysiologic effects:** Changes in the PR, QT, and QTc intervals were noted during left ventricular injection, but there was wide variability among patients with changes from baseline ranging from -38% to 37%. However, no significant differences were noted between the agents. Electrophysiologic changes occurring immediately after coronary injection are listed in Table II. There was a significant difference in the PR interval during left but not right coronary artery injection between iodixanol, which caused maximal prolongation of <1.5%, and iohexol during the time of monitoring. There was significantly more ST-segment depression in the iohexol than in the iodixanol group with both left and right coronary angiography, but this was not found to be clinically relevant (p <0.023).

Many patients, 74% with iodixanol and 77% with iohexol, had some sort of arrhythmia during catheterization (p = NS), both before and after contrast administration. There was 1 episode of nonsustained ventricular tachycardia not requiring treatment and 1 episode of ventricular fibrillation, both occurring with iohexol.

**Adverse events:** There were no significant differences in adverse events when the 2 agents were compared, with 35% of patients in both groups experienc-
ing a generally mild adverse event. Only 5 (2 with iodixanol and 3 with iohexol) were considered to be definitely related to the contrast material. In all, there were only 4 serious events in 3 patients (3%) with iodixanol and 5 events in 5 patients (5%) with iohexol. Only 1 serious event, ventricular fibrillation with iohexol, was considered definitely related to contrast. Two others, pulmonary edema and severe chest pain, both with iohexol, were considered of uncertain relation to contrast. None of the 4 serious events occurring with iodixanol were considered to be related to contrast. There were no deaths and all patients recovered without sequelae.

After the procedure, there were variations in heart rate and blood pressure that were considered to be of clinical importance in 4% of the iodixanol group and 13% of the iohexol group (p = 0.024), but none were considered to be directly attributable to contrast. Analysis of laboratory data showed no significant trends that suggested toxicity from either agent. Specifically, 6 patients with iodixanol and 7 with iohexol had increases in serum creatinine, both >40% of the span of the reference range and above the normal range. Only 2 patients had increases in serum creatinine of >0.5 mg/dl 3 days after catheterization. These patients received io-

![Graphs showing hemodynamic changes after left coronary arteriography. No significant differences are noted between iohexol and iodixanol.](image)
hexol and had baseline creatinine levels of 1.3 and 1.9 mg/dl, and maximal serum creatinine levels of 3.7 and 2.6 mg/dl, respectively.

Injection-associated discomfort: Injection-associated discomfort was reported in 77% and 86% of patients receiving iodixanol and iohexol, respectively (p = 0.145). As would be expected, in the majority, this was a transient warm feeling, which lasted <2 minutes. However, more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p <0.001).

Because of differences in individual practices among centers, there were some minor intercenter differences found in patient demographics and other parameters that were consistent between the agents.

**DISCUSSION**

While additives and calcium-binding properties play a role in many of the hemodynamic and electrophysiologic effects caused by contrast agents, high osmolality also has a significant effect on a variety of physiologic processes. Lower osmolality is achieved either by in-

---

**LEFT VENTRICULAR INJECTION**

**LV SYSTOLIC PRESSURE**

**LV END-DIASTOLIC PRESSURE**

**HEART RATE**

*FIGURE 4. Hemodynamic changes after left ventricular (LV) angiography. No significant differences are noted between iohexol and iodixanol.*

62 THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 74 JULY 1, 1994
creasing the number of iodine atoms per molecule of the contrast agent, as with the ionic dimeric agent ioxaglate, or by eliminating the need to ionize in solution, as with the conventional nonionic agents iopamidol, ioversol, or iohexol. In either case, these agents provide 3 iodine atoms per osmotically active particle in solution, thus making them ratio 3 agents with approximately half of the osmolality of ratio 1.5 agents. Iodixanol contains 6 iodine atoms per particle and does not ionize in solution, thus making it a ratio 6 agent. With the addition of sodium and calcium the osmolality is equal to serum.

In vitro experiments suggest that iodixanol is not significantly different from other nonionic agents as to changes in red cell morphology and aggregation induced by contact.10,11 Data from intact animal and other models suggest favorable hemodynamic effects of iodixanol when compared with conventional nonionic agents.12–14

Published clinical experience with iodixanol is limited. Gavant and Siegle15 reported it to be safe and effective for intravenous use for excretory urography. Summarized initial data from phase I and II trials in Europe using iodixanol for intraarterial and intravenous use also show a good safety profile.6 Klow et al16 performed cardiac angiography with iodixanol in 14 stable patients, and then compared it with iohexol in 72 other patients and found good patient tolerance. They found no heart rate or hemodynamic changes during left ventricular angiography but did not discuss these parameters after coronary injection.

Nonionic contrast agents in general have been previously shown to have much less severe hemodynamic and electrophysiologic effects than high osmolar agents when used for cardiac angiography. It is not clear whether this is solely due to the decrease in osmolality or whether there is less chemotoxicity with these agents. Iodixanol has a lower osmolality than available nonionic agents, but has sodium and calcium added to the formulation. Whether the addition of these electrolytes in a ratio similar to blood interacts with the reduction in osmolality in some way to alter the toxicity is not known. It would appear from the current study that further improvement in clinically relevant effects of osmolality may not be measurable when compared with the improvement achieved with conventional nonionic contrast, at least in low-risk patients. Studies in patients at high risk for complications are necessary to help further define the role of iodixanol in cardiac angiography.